Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00410605 · BASELINE

Baseline characteristics

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma · Source last updated 2017-09-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      39
    units
    Participants
groups
  1. description
    Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
    id
    BG000
    title
    Bevacizumab, Dexamethasone, and Lenalidomide
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      40-49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          15
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          24
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          39
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      39
    units
    Participants
groups
  1. description
    Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
    id
    BG000
    title
    Bevacizumab, Dexamethasone, and Lenalidomide
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      40-49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      50-59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      60-69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      70-79 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      80-89 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          15
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          24
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          39
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice